Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Articles from other publishers (12)
Mingnan Cao, Chen Pan, Yue Tian, Li Wang, Zhigang Zhao & Bin Zhu. (2023) Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis. International Journal of Clinical Pharmacy 45:3, pages 689-697.
Crossref
Crossref
Woosuk Choi, Shawn Choe, Jingjun Lin, Michael T. Borchers, Beata Kosmider, Robert Vassallo, Andrew H. Limper & Gee W. Lau. (2020) Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling. Mucosal Immunology 13:4, pages 637-651.
Crossref
Crossref
Linda Wu, Christopher B. Nahm, Nigel B. Jamieson, Jaswinder Samra, Roderick Clifton‐Bligh, Anubhav Mittal & Venessa Tsang. (2020) Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clinical Endocrinology 92:5, pages 396-406.
Crossref
Crossref
Yufang Liu, Xiaomei Zhang, Sanbao Chai, Xin Zhao & Linong Ji. (2019) Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. Journal of Diabetes Research 2019, pages 1-10.
Crossref
Crossref
Jetty A. Overbeek, Marina Bakker, Amber A.W.A. van der Heijden, Myrthe P.P. van Herk-Sukel, Ron M.C. Herings & Giel Nijpels. (2018) Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 34:5, pages e3004.
Crossref
Crossref
Mathieu Boniol, Matteo Franchi, Maria Bota, Agnès Leclercq, Joeri Guillaume, Nancy van Damme, Giovanni Corrao, Philippe Autier & Peter Boyle. (2018) Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies. Diabetes Care 41:2, pages 286-292.
Crossref
Crossref
Bianca Hemmingsen, David P Sonne, Maria-Inti Metzendorf & Bernd Richter. (2017) Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017:5.
Crossref
Crossref
Přemysl Frič, Jan Škrha, Aleksi Šedo, Petr Bušek, Klára Kmochová, Martin Laclav, Svatopluk Solař, Bohuš Bunganič & Miroslav Zavoral. (2016) Early pancreatic carcinogenesis – risk factors, early symptoms, and the impact of antidiabetic drugs. European Journal of Gastroenterology & Hepatology 28:7, pages e19-e25.
Crossref
Crossref
Bianca Hemmingsen, Jesper Krogh, Maria-Inti Metzendorf & Bernd Richter. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Sean M. Brady, Michael P. Kane & Robert S. Busch. (2016) GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis. AACE Clinical Case Reports 2:2, pages e82-e85.
Crossref
Crossref
Liberata Sportiello, Concetta Rafaniello, Cristina Scavone, Cristiana Vitale, Francesco Rossi & Annalisa Capuano. (2016) The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology 202, pages 731-735.
Crossref
Crossref
Alok Sharma, Geetanjali Paliwal, Nisha Upadhyay & Archana Tiwari. (2015) RETRACTED ARTICLE: Therapeutic stimulation of
GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Crossref